- Credit Suisse has initiated coverage on Eli Lilly And Co (NYSE:LLY) with an Outperform rating and a price target of $395.
- Management has delivered a remarkable performance against a challenging backdrop. However, with the stock at an all-time high valuation, the key question is whether it can continue this momentum.
- The analysts are optimistic and believe that Eli Lilly has industry-leading growth in the short- and long-term, unhampered by loss of exclusivity (LOE).
- Related: Eli Lilly Says Q3 Earnings Supported By Key Products and Volume, Cuts FY22 Outlook.
- Credit Suisse notes some turbulence if Mounjaro cannot hit short-term quarterly numbers, with supply concerns, but in the long term, it is expected to be one of the most valuable drugs in Pharma.
- Several investors remain offside given the binary donanemab TRAILBLAZER-2 Alzheimer’s Phase 3 data expected in mid-2023, but analysts think the setup is skewed to the upside.
- The analyst believes the Street is underappreciating the obesity market size given the impressive data and favorable reimbursement with Wegovy. Donanemab (Alzheimer’s) should continue to dominate the headlines.
- Price Action: LLY shares are down 0.23% at $359.93 on the last check Friday.
Silicon Wars: Samsung Unveils Next-Gen AI Chips to Challenge TSMC’s Dominance
Samsung Electronics Co Ltd (OTC
) showcased its cutting-edge foundry technologies and AI-driven strategic vision at the Samsung Foundry Forum in San Jose, revealing new process nodes, SF2Z and SF4U, aimed at boosting AI chip production. These innovations underscore Samsung's commitment to leading the AI semiconductor revolution, aiming to challenge the market dominance of Taiwan Semiconductor Manufacturing Co.
